Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.

Inclusion criteria: * Type 2 diabetes and renal failure in use of NPH regular insulin or fast-acting analog and HbA1c \>= 8%. * Albuminuria or microalbuminuria diabetic retinopathy. * Creatinine clearance \< 60 mL/min/1,73 m2 and \>30 mL/min/1,73 m2 Exclusion criteria: * Hypersensibility to insulin glargine or any other component of the insulin formulation. * Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months. * History of diabetic ketoacidosis or positive GAD antibodies. * Advanced retinopathy needing laser therapy. * Diagnosed advanced neuropathy * Severe hepatic disease or active hepatitis. * Cardiac failure class III or IV (NYHA). * Patients on hemodialysis. * Diagnosed cancer. * Active infection. * Current therapy with steroids. * Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.